Cho YM, Deerochanawong C, Seekaew S, et al. - In patients with type 2 diabetes mellitus, researchers tested the effectiveness and safety of gemigliptin added on to a stable dose of insulin alone or insulin in combination with metformin. Study participants were randomized 2:1 to receive gemigliptin 50 mg or placebo once daily as add-on to background therapy with insulin or insulin plus metformin for 24 weeks after a 2-week run-in period. Baseline features were comparable in terms of HbA1c (8.1%) between the gemigliptin (n = 188) and placebo (n = 95) groups. Investigators found that gemigliptin added to insulin alone or insulin in conjunction with metformin exhibited superior glycemic control over placebo, and was well tolerated for 24 weeks in patients with type 2 diabetes mellitus without causing weight gain or increasing hypoglycemia incidence.